Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 6/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1969539 | 1.00 | CA12 (0.51) | CA12CA9ALDH1A1CASP3MEN1 | |
| SCHEMBL2866493 | 0.84 | CA12 (0.49) | CA12CA9ALDH1A1CASP3MEN1 | |
| SCHEMBL4017572 | 0.82 | ALDH1A1 (0.55) | CA12CA9ALDH1A1CASP3MEN1 | |
| SCHEMBL12391716 | 0.80 | ALDH1A1 (0.47) | CA12CA9ALDH1A1MEN1KMT2A | |
| SCHEMBL11285299 | 0.80 | ALDH1A1 (0.49) | CA12CA9ALDH1A1CASP3GSK3B | |
| SCHEMBL21744814 | 0.80 | ALDH1A1 (0.49) | CA12CA9ALDH1A1CASP3GSK3B | |
| SCHEMBL11285292 | 0.80 | ALDH1A1 (0.49) | CA12CA9ALDH1A1CASP3GSK3B | |
| SCHEMBL18591432 | 0.80 | ALDH1A1 (0.49) | CA12CA9ALDH1A1CASP3KMT2A | |
| SCHEMBL16623099 | 0.79 | ALDH1A1 (0.51) | CA12CA9ALDH1A1CASP3SMN1; SMN2 | |
| SCHEMBL1973155 | 0.78 | ALDH1A1 (0.50) | CA12CA9ALDH1A1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100273931-A1 | DECARBOXYLATING BLOCK COPOLYMERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-10-28 | — | — | US | claimed |
| EP-0974607-B1 | Coating compositions and inks | DU PONT (US) | 2004-09-29 | — | — | EP | claimed |
| EP-0974626-B1 | Aqueous pigmented ink jet inks for printing on vinyls | DU PONT (US) | 2004-05-19 | — | — | EP | claimed |
| EP-0826751-B1 | Aqueous dispersions containing graft copolymers as the dispersant | DU PONT (US) | 2004-04-28 | — | — | EP | claimed |
| US-8956798-B2 | Process for producing toner for electrophotography | KAO CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| EP-2730419-A1 | Printing method | Mimaki Engineering Co., Ltd. (JP) | 2014-05-14 | — | — | EP | disclosed |
| US-8362106-B2 | Decarboxylating block copolymers | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2509424-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2012-10-17 | — | — | EP | disclosed |
| US-8013053-B2 | Water-based inks for ink-jet printing | KAO CORPORATION (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20110207704-A1 | Novel Oxadiazole Compounds | ABBOTT LABORATORIES (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110183249-A1 | PROCESS FOR PRODUCING TONER FOR ELECTROPHOTOGRAPHY | KAO CORPORATION (JP) | 2011-07-28 | — | — | US | disclosed |
| US-7964660-B2 | Process for producing aqueous pigment dispersion | KAO CORPORATION (JP) | 2011-06-21 | — | — | US | disclosed |
| WO-2011071570-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20100273931-A1 | DECARBOXYLATING BLOCK COPOLYMERS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-10-28 | — | — | US | disclosed |
| US-7795327-B2 | Water-based inks for ink-jet printing | KAO CORPORATION (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070149647-A1 | Water-based inks for ink-jet printing | KAO CORPORATION | 2007-06-28 | — | — | US | disclosed |
| US-20060052480-A1 | Water-based inks for ink-jet printing | KAO CORPORATION (JP) | 2006-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207704-A1 | Novel Oxadiazole Compounds | S1PR3, S1PR1, S1PR2 | CA12 4870/4885CA9 4876/4885ALDH1A1 4044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.